Not sure there is no audit trail. The books have to be balanced even if one 1 trade has been made and you could trace the trade to the broker and terminal it was made from if you wanted. This is the thing about conspiracy and myth. You end up believing the small things but ignore the corruption happening in-plane sight. Think about this. Say the 2.5 million the HNWI put in was 10% of their net worth and say they were given extra data we the private investors are not privy to. Then imagine that my investment in SAR is 10% of my total worth. Why should they get extra data and not me? It's insider dealing under the guise of Institutional investing. I think they chuck the 1 codes in on purpose to keep up the pretence and perpetuate the myth.
I very rarely filter people because I do like to listen to both sides but the negative posts with no context, I mean why would you even go to the trouble? i don't think they are paid to do it. I think they are bitter because they are losing elsewhere. A quick glance at their other posts tells you all you need to know about them. The ones like sly don't even know what they are mad about. They are the 21 century equivalent of the angry bloke sat on his own in the boozer, mad at the world because they feel inadequate.
The current MC feels about right as we wait for what could be transformational news where the second quarter of 2021 sees Sareum rerating in line will other biotech companies. One thing for sure. When the news drops (the data) if good. there will be a mass scramble to get in. I think they will release partnering news at the same time though. I'm just glad I'm on the right side this time. Watched many multi-baggers from the sidelines over the years. Never bought in thinking I missed the bottom. This time I'm in and staying in.
It's a long and complex answer, i fear. For me, the value is decided by the market and for years we haven't been close enough to the transformational news. We are now. With 4 compounds in trials, the company could easily be worth a billion or more. We are now less than a year from that milestone. The value will then be decided based on how big the on licence deals are worth against the risk of failure. There are few accountants here and if you haven't already, look at RMM's valuation. This was pre covid POC. We are waiting to see what he thinks after the POC news is in.
Both are equally important. On a side note to this, a client of mine has just had Covid after being vaccinated twice. He's waiting to see which variant it was. He had the Astra jab. He is fit and healthy but it still knocked him for 6 for a week. Other vaccinated people may not be so lucky.
I also don't see any reason why a licence shouldn't be worth £800 million in milestones. The severe respiratory market is a big one after all. That would see us at 28p by the year-end without the other compounds in play.
yes, we have to trial on the patients available. If the summer\autumn coincides with a third wave. They will probably get approval for P2. Maybe a P1a where it is given to healthy but positive covid patients. Planning the strategy is going to be crucial as ethics come into play. SNG aren't in Agile but it means they can trial in India but not being on Agile will also hold them back when seeking emergency approval. I'm sure there is more than Tim, John and UKRI thinking about this.
For the trials, I think they will do something like the vaccine trials. A short P1 in healthy adults, keep that running, then start P2 in covid patients. I do think getting approval by the end of the year is ambitious but if it shows efficacy in seriously ill patients, it will be fast-tracked. All three phases will continue well into next year and the year after just as the vaccines are still in trials now.